There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Protagonist Therapeutics (PTGX), Unum Therapeutics (UMRX) and Gritstone Oncology (GRTS) with bullish sentiments.
Protagonist Therapeutics (PTGX)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Protagonist Therapeutics, with a price target of $23.00. The company’s shares closed last Monday at $10.37.
According to TipRanks.com, Tsao is a 1-star analyst with an average return of -1.8% and a 46.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Amag Pharmaceuticals, and Revance Therapeutics.
Protagonist Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.00, representing a 156.4% upside. In a report issued on November 8, Nomura also reiterated a Buy rating on the stock with a $29.00 price target.
See today’s analyst top recommended stocks >>
Unum Therapeutics (UMRX)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Unum Therapeutics today and set a price target of $18.00. The company’s shares closed last Monday at $1.06, close to its 52-week low of $1.02.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.1% and a 45.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Unum Therapeutics with a $13.00 average price target.
Gritstone Oncology (GRTS)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Gritstone Oncology today and set a price target of $16.00. The company’s shares closed last Monday at $7.14, close to its 52-week low of $7.00.
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -8.8% and a 31.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals, ThermoGenesis Holdings, and IntelGenx Technologies.
Currently, the analyst consensus on Gritstone Oncology is a Moderate Buy with an average price target of $16.00, implying a 121.9% upside from current levels. In a report issued on November 10, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
